Cardiovascular Function in Acute Leukemia

Abramson Cancer Center at Penn Medicine84 enrolled

Overview

An observational, prospective study to describe the rates and predictors of cardiovascular events in patients with acute leukemia.

Patients recently diagnosed with acute leukemia and who will initiating chemotherapy will be enrolled and followed serially with blood collection, echocardiogram, arterial applanation tonometry, and questionnaires for 1 year.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Leukemia, Myeloid, Acute Leukemia, Lymphoid, Acute Cardiotoxicity

Interventions

observation onlyOTHER

No intervention, observational study only

Eligibility

Sex: ALLMin age: 18 YearsMax age: 90 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Older than 18 years of age, * New diagnosis of untreated acute leukemia (prior treatment for myelodysplastic syndrome or myeloproliferative neoplams or prior treatment with an anthracycline for breast cancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma or another diagnosis will be included). * Signed the informed consent form Exclusion Criteria: • Unable to provide informed consent

Locations (1)

Abramson Cancer Center of the University of Pennsylvania

Philadelphia, Pennsylvania, United States

Outcomes

Primary Outcomes

Left Ventricular dysfunction

defined as a reduction in Left Ventricular Ejection Fraction of more than 10 percentage points from baseline and to less than 50%.

Time frame: 1 year

Secondary Outcomes

Incidence of Cardiovascular Events

Time frame: 1 year

Incidence of Symptomatic Heart Failure

Time frame: 1 year

Incidence of Cardiac Death and all mortality

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.